Advocates argue that indication-level pricing can bring new products on stream and results in wider patient access to new therapies. That’s a good thing, right? Maybe, but for indication-level pricing to work payers would have to overcome a range of practical and costly administrative, data collection and regulatory obstacles. There is also the perennial payers’ suspicion that profit underlies pharma’s enthusiasm. Pharma wants optimum price, payers want value and patients need access–but is indication-level pricing a model that is ever likely to deliver at pace and scale, and what can pharma do now to progress the argument for indication-level pricing with payers?
Understanding in detail what payers see as the main issues and areas of objection is critical. That is why, in Indication-level Pricing: Payer insights, we interviewed experienced payers from the US and Europe to help you evaluate where–and how–pharma can act.
Payers explore indication-level pricing challenges
- What are the problems caused by having a single price for a multi-indication drug?
- Different brand names or delivery/dosage forms? Discounts by indication? Outcomes-based payments? What models find traction with payers and what are their objections?
- How should value be determined for indication-level pricing?
- What are the data challenges for implementing indication-level pricing and how can they be overcome?
- What are the contractual and financial flows challenges for implementing indication-level pricing?
- How could misuse of indication-level pricing be overcome?